These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35689641)

  • 1. Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.
    Shiner B; Huybrechts K; Gui J; Rozema L; Forehand J; Watts BV; Jiang T; Hoyt JE; Esteves J; Schnurr PP; Ray K; Gradus JL
    Am J Epidemiol; 2022 Aug; 191(9):1614-1625. PubMed ID: 35689641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
    Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
    J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
    J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
    Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World.
    de Ávila Machado MA; de Moura CS; Klein M; Winthrop K; Carleton B; Abrahamowicz M; Feld J; Curtis JR; Beauchamp ME; Bernatsky S
    J Manag Care Spec Pharm; 2019 Jun; 25(6):697-704. PubMed ID: 31134863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
    Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
    Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
    Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.
    Amjad W; Zhang T; Maheshwari A; Thuluvath PJ
    J Clin Exp Hepatol; 2022; 12(2):329-335. PubMed ID: 35535089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
    Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
    Chen P; Jin M; Cao Y; Li H
    Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
    Mangia A; Scaglione F; Toniutto P; Pirisi M; Coppola N; Di Perri G; Alvarez Nieto G; Calabrese S; Hernandez C; Perrone V; Degli Esposti L; Fagiuoli S
    Int J Environ Res Public Health; 2021 Jul; 18(13):. PubMed ID: 34281080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
    Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
    J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
    [No Abstract]   [Full Text] [Related]  

  • 20. Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
    Manabe T; Tadokoro T; Nakahara M; Ohura K; Fujita K; Tani J; Morishita A; Ogawa C; Masaki T
    Intern Med; 2023 Sep; 62(17):2507-2511. PubMed ID: 36450472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.